NASDAQ:EXEL - Exelixis, Inc.
$21.52
 $0.30
+1.41%
4:20PM EDT
2019-02-22
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  EXEL     avg for
industry  
  avg for
sector  
42 stocks weight:  89. 26   0. 00   0. 00  
42 stocks rank:  1. 94 K 2. 00 K 1. 08 K
# analyst opinions:  9. 00   14. 68   14. 18  


target price low:  20. 00   90. 05   118. 16  
target price avg:  28. 78   115. 98   142. 03  
target price high:  36. 00   141. 44   162. 86  
1-yr high:  29. 53   124. 28   143. 16  
last close:  21. 52   102. 75   129. 63  
50-day avg:  21. 62   98. 90   122. 76  
200-day avg:  19. 65   100. 04   123. 17  
1-yr low:  13. 65   78. 22   100. 14  
volume:  3. 92 M 2. 36 M 4. 94 M
50-day avg volume:  4. 07 M 3. 14 M 4. 85 M
200-day avg volume:  4. 13 M 3. 12 M 4. 26 M

1-day return:  1. 41 % 1. 74 % 0. 96 %
this week return:  -3. 32 % -0. 72 % -0. 25 %
12-wk return:  5. 96 % 1. 23 % -0. 75 %
52-wk return:  -26. 35 % -2. 03 % 16. 23 %

enterprise value (EV):  5. 76 B 54. 82 B 107. 48 B
market cap:  6. 42 B 47. 12 B 97. 54 B
EBITDA:  442. 69 M 4. 72 B 7. 18 B
enterprise multiple (EV/EBITDA):  13. 02   9. 03   16. 84  
enterprise/revenue (EV/R):  6. 75   31. 24   24. 21  
total revenue:  853. 83 M 11. 05 B 40. 03 B
total debt:  14. 98 M 13. 41 B 16. 70 B
debt/equity:  1. 64   41. 61   80. 63  
net income (common):  690. 07 M 2. 34 B 3. 61 B

shares outstanding:  298. 98 M 594. 48 M 1. 22 B
shares:  294. 62 M 592. 96 M 1. 15 B
shares short:  15. 03 M 10. 54 M 11. 92 M
shares short prior month:  12. 36 M 11. 90 M 11. 87 M
short ratio:  3. 50   4. 86   3. 18  
short % of float:  5. 88 % 6. 23 % 2. 78 %
total cash/share:  2. 12   11. 99   10. 04  
total cash:  634. 62 M 7. 30 B 7. 05 B

book value:  3. 06   15. 06   28. 80  
price/book:  7. 02   -0. 58   -2. 51  
gross profits:  827. 48 M 8. 33 B 19. 31 B
operating margins:  51. 40 % -466. 96 % -635. 17 %
EBITDA margins:  51. 85 % 13. 54 % 22. 51 %
profit margins:  80. 82 % 6. 67 % 10. 02 %
gross margins:  96. 91 % 48. 21 % 54. 28 %

1-yr max volatility:  16. 45 % --- ---
1-yr mean volatility:  -0. 06 % 0. 01 % 0. 07 %

1-yr EPS:  2. 21   3. 08   4. 11  
forward EPS:  1. 29   4. 75   7. 18  
P/E:  9. 74   15. 54   29. 27  
forward P/E:  16. 47   -20. 90   3. 33  
PE/G:  0. 04   1. 33   6. 07  
growth:  276. 70 % 755. 42 % 114. 65 %
earnings high:  0. 37   1. 33   1. 68  
earnings avg:  0. 26   0. 97   1. 54  
earnings low:  0. 20   0. 70   1. 41  
revenue high:  267. 53 M 2. 81 B 11. 37 B
revenue avg:  226. 79 M 2. 70 B 11. 06 B
revenue low:  200. 00 M 2. 61 B 10. 84 B
earnings growth:  836. 20 % 161. 77 % 38. 17 %
1-qtr earnings growth:  835. 60 % 162. 86 % 36. 50 %
return on equity:  114. 92 % 102. 34 % 26. 90 %
revenue growth:  90. 40 % 717. 29 % 107. 00 %
revenue/share:  2. 87   14. 67   60. 08  

beta (1yr vs S&P500):  1. 47   1. 22   0. 94  
sharpe (1yr):  -0. 30   0. 14   1. 05  

held % insiders:  1. 61 % 6. 40 % 3. 16 %
held % institutions:  78. 31 % 79. 62 % 70. 81 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-22 : EXEL
.    + 6.849 =         6.849 :: INITIAL WEIGHT
.   + 104.81 =       111.659 :: inverse volume-to-price addition
.    + 482.2 =       593.859 :: spline projection addition
.  + 552.043 =      1145.902 :: notable performance addition
.  - 121.075 =      1024.828 :: poor performance penalty
.    x 0.841 =       861.622 :: one-year gains+dividend factor
.    x 2.908 =      2505.627 :: 13 weeks' performance factor
.    x 1.478 =      3703.176 :: industry recommendation factor
.    x 1.216 =      4503.325 :: EV/R factor
.    x 3.704 =     16678.471 :: earnings growth factor
.    x 1.605 =     26766.271 :: return on equity factor
.    x 2.269 =     60733.369 :: revenue growth factor
.    x 1.134 =     68865.168 :: short ratio factor
.     x 2.14 =    147351.047 :: price-to-book factor
.    x 1.019 =    150219.591 :: debt-to-equity factor
.    x 1.248 =    187539.529 :: EBITDA multiple vs industry factor
.    x 1.181 =    221514.082 :: EBITDA multiple factor
.    x 1.095 =    242569.542 :: 5-day avg > 200-day avg
.      x 1.1 =     266868.22 :: 50-day avg > 200-day avg
.    x 2.314 =    617528.586 :: P/E weight
.    x 2.209 =   1364095.398 :: PE/G factor
.    x 1.564 =   2134108.118 :: beta factor
.    x 0.301 =     641948.36 :: sharpe factor
.    x 0.973 =    624887.506 :: target low factor
.    x 1.194 =    745871.457 :: target mean factor
.    x 1.082 =    807053.945 :: target high factor
.    x 1.012 =    816990.366 :: industry 12-weeks return
.     x 0.94 =     768097.16 :: "drift" penalty 2 days ago
.      x 1.0 =    767899.279 :: overall "drift" factor
.    x 0.835 =    641542.604 :: largest single-day jump factor
.     x 1.01 =    647953.935 :: mean volatility factor
.    x 1.098 =    711320.195 :: 42-day mean volatility factor
.      x 1.0 =    711246.476 :: factor hist industry gain for week 07
.   cubeRoot =        89.263 :: reduced for readability
.                     89.263 :: FINAL WEIGHT for NASDAQ:EXEL


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org